GlassScriptPhysician profile
Zeeshan Choudhry
NPI 1770210924
$6,659.92
in general payments reported to CMS, 2019-2025
22 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $158 · 2023: $1,701 · 2024: $2,438 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,490 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,489.86 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,827.52 | 2022-2025 | Caplyta |
| Abbvie INC. | $965.06 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $784.39 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $486.44 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $484.40 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $428.64 | 2022-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $337.03 | 2023-2025 | Ingrezza |
| Corium, LLC | $259.27 | 2022-2024 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $213.67 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $157.40 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Axsome Therapeutics, INC. | $117.12 | 2023-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $101.55 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $100.65 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $98.12 | 2023 | Uzedy, Austedo Xr |
| Lundbeck LLC | $95.53 | 2023-2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $61.75 | 2022-2023 | Trintellix |
| Noven Therapeutics, LLC | $33.99 | 2025 | Xelstrym |
| Luye Pharma (USA) LTD. | $30.08 | 2025 | Erzofri Extended-Release |
| Tempus Ai, INC | $22.58 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.61 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $18.11 | 2025 | Zurzuvae |
| Neuronetics, INC. | $17.01 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeeshan Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.